Insmed (INSM) has drawn fresh investor attention after reporting first quarter 2026 results that combined significant revenue contributions from BRINSUPRI and ARIKAYCE with a smaller net loss and reiterated full year guidance.

Despite the solid Q1 update and reiterated guidance, the stock has recently pulled back, with a 30 day share price return of down 21.93% and a year to date share price return of down 33.38%. At the same time, the 1 year total shareholder return sits at 79.84%, suggesting long term momentum has been strong while near term enthusiasm has cooled.

If you are looking beyond a single biotech story, this is a good moment to see what else is moving in healthcare AI and related therapies through 33 healthcare AI stocks

With Insmed’s shares down sharply in recent weeks, yet still carrying a very strong 1 year return and trading at a large discount to published analyst targets, you have to ask whether this is a fresh entry point or whether future growth is already reflected in the price.

Most Popular Narrative: 44.5% Undervalued

At a last close of $117.99 against a narrative fair value of $212.50, the most followed view on Insmed is building in a wide valuation gap that hinges on execution in respiratory launches and margin expansion.

The anticipated U.S. launch of brensocatib in bronchiectasis in the third quarter of 2025 is a major catalyst, expected to significantly increase revenue once it hits the market and starts generating sales late in Q3. The upcoming Phase II data for TPIP in PAH by mid-2025 and brensocatib in CRS without nasal polyps by the end of 2025 are key clinical milestones that could enhance future revenue streams if positive.

Want to see what justifies that gap between price and fair value? The narrative focuses on aggressive revenue expansion, sharply improving margins and a premium future earnings multiple. Curious which assumptions do the heavy lifting here?

Result: Fair Value of $212.50 (UNDERVALUED)

However, this story can change quickly if FDA review timelines slip or payer pushback slows brensocatib uptake, especially with mixed signals from other pipeline trials.

Another View: Rich On Sales Metrics

The first narrative leans on future cash flows and a large discount to fair value, but the current sales based valuation paints a different picture. At a P/S of 31.2x versus a fair ratio of 16.7x, the US Biotechs industry at 10.6x and peers at 8.5x, Insmed looks expensive on today’s revenue, which raises the question of how much execution risk you are comfortable with at this price.

Next Steps

With sentiment clearly split between enthusiasm for potential rewards and concern about real risks, it makes sense to look at the data yourself and quickly form an opinion. To help you weigh both sides in one place, take a closer look at the 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If you stop with just one stock, you risk missing other opportunities that better match your goals, risk comfort and income needs across the market.

• Target potential mispricings by scanning for companies that combine quality fundamentals with attractive valuations through the 47 high quality undervalued stocks.
• Strengthen your income stream by focusing on companies that pair stability with higher yields using the 14 dividend fortresses.
• Dial back portfolio risk by concentrating on companies that score well on resilience through the 68 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.